MDT

86.16

-0.16%↓

113.06

-1.43%↓

VEEV

170.81

-1.7%↓

HQY

81.44

-2.7%↓

PHR.US

9.02

+2.73%↑

MDT

86.16

-0.16%↓

113.06

-1.43%↓

VEEV

170.81

-1.7%↓

HQY

81.44

-2.7%↓

PHR.US

9.02

+2.73%↑

MDT

86.16

-0.16%↓

113.06

-1.43%↓

VEEV

170.81

-1.7%↓

HQY

81.44

-2.7%↓

PHR.US

9.02

+2.73%↑

MDT

86.16

-0.16%↓

113.06

-1.43%↓

VEEV

170.81

-1.7%↓

HQY

81.44

-2.7%↓

PHR.US

9.02

+2.73%↑

MDT

86.16

-0.16%↓

113.06

-1.43%↓

VEEV

170.81

-1.7%↓

HQY

81.44

-2.7%↓

PHR.US

9.02

+2.73%↑

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Open

SectorHealthcare

508.7 -5.67

Buy Sell

Overview

Share price change

24h

Current

Min

504.13

Max

544.36

Key metrics
By Trading Economics
Income	56M -59M
Sales	34M 321M
Profit margin	-18.243
Employees	915
EBITDA	56M -50M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+28.89% upside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	1B 12B
Previous open	514.37
Previous close	508.7

News Sentiment

By Acuity

34%

66%

113 / 349 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

6 kwi 2026, 23:17 UTC

Earnings

Samsung Forecasts Record First-Quarter Operating Profit

6 kwi 2026, 23:00 UTC

Hot Stocks

Stocks to Watch: Health Insurers, Mawson, Owlet

6 kwi 2026, 22:13 UTC

Major Market Movers

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6 kwi 2026, 21:46 UTC

Acquisitions, Mergers, Takeovers

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6 kwi 2026, 17:09 UTC

Major Market Movers

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6 kwi 2026, 16:56 UTC

Major News Events

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6 kwi 2026, 14:47 UTC

Major Market Movers

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7 kwi 2026, 00:00 UTC

Major News Events

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6 kwi 2026, 23:58 UTC

Market Talk

Major News Events

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6 kwi 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6 kwi 2026, 23:36 UTC

Market Talk

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6 kwi 2026, 23:15 UTC

Market Talk

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6 kwi 2026, 22:52 UTC

Market Talk

Global Equities Roundup: Market Talk

6 kwi 2026, 22:52 UTC

Market Talk

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6 kwi 2026, 22:14 UTC

Market Talk

Correction to Live Cattle Futures Article

6 kwi 2026, 20:56 UTC

Market Talk

Mexican Private Consumption Fell in January -- Market Talk

6 kwi 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

6 kwi 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6 kwi 2026, 19:58 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 kwi 2026, 19:58 UTC

Market Talk

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6 kwi 2026, 19:11 UTC

Market Talk

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6 kwi 2026, 19:06 UTC

Market Talk

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6 kwi 2026, 19:03 UTC

Market Talk

Global Energy Roundup: Market Talk

6 kwi 2026, 19:03 UTC

Market Talk

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6 kwi 2026, 18:36 UTC

Acquisitions, Mergers, Takeovers

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 kwi 2026, 17:59 UTC

Market Talk

Major News Events

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6 kwi 2026, 17:13 UTC

Acquisitions, Mergers, Takeovers

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 kwi 2026, 16:33 UTC

Market Talk

Oil Futures Steady as Market Awaits Trump -- Market Talk

6 kwi 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 kwi 2026, 14:59 UTC

Earnings

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

28.89% upside

12 Months Forecast

Average 704.88 USD 28.89%

High 964 USD

Low 529 USD

Based on 9 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

113 / 349 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.